PERSISTENCE OF PH+/CD34+ CELLS IN CHRONIC MYELOID LEUKEMIA PATIENTS IN PROLONGED COMPLETE CYTOGENETIC REMISSION FOLLOWING IMATINIB MESYLATE TREATMENT


https://doi.org/10.4081/jsas.2009.329
Vol. 1 No. 1 (2009)
Submitted: 10 January 2012
Accepted: 10 January 2012
Published: 10 January 2012
Abstract Views: 766
PDF: 1212
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

  • M. Defina
    info@pagepres.org
    Ematology and Transplant Unit, Dept. of Clinical Medicine and Immunological Sciences, University of Siena, Italy.
  • M. Bocchia Ematology and Transplant Unit, Dept. of Clinical Medicine and Immunological Sciences, University of Siena, Italy.
  • I. Ippoliti Ematology and Transplant Unit, Dept. of Clinical Medicine and Immunological Sciences, University of Siena, Italy.
  • A. Gozzetti Ematology and Transplant Unit, Dept. of Clinical Medicine and Immunological Sciences, University of Siena, Italy.
  • S. Calabrese Ematology and Transplant Unit, Dept. of Clinical Medicine and Immunological Sciences, University of Siena, Italy.
  • R. Crupi Ematology and Transplant Unit, Dept. of Clinical Medicine and Immunological Sciences, University of Siena, Italy.
  • I. Chitarrelli Ematology and Transplant Unit, Dept. of Clinical Medicine and Immunological Sciences, University of Siena, Italy.
  • F. Lauria info@pagepres.org, Italy.
Chronic myelogenous leukemia (CML) is characterized by a clonal expansion of a hematopoietic stem cell possessing a reciprocal translocation between chromosomes 9 and 22, the Philadelphia chromosome, as identified cytogenetically or molecularly (RT-PCR). CML accounts for 15% of adult leukemias. The disease progresses from a chronic phase through an accelerated phase to a blast phase. In the past, the National Comprehensive Cancer Network had suggested that there were three primary treatments available for CML which included: allogeneic bone marrow transplantation (BMT), IFN-α with or without cytarabine, and imatinib mesylate (Glivec®). It has been shown that Glivec is superior to the combination of interferon plus cytarabine. Although BMT can be a curative treatment for CML it is not usually used as a front-line therapy, due to limited donor availability and high toxicity of the procedure. Five-year survival rates following HLA-matched transplants are approximately 75% for patients in chronic phase.

Defina, M., Bocchia, M., Ippoliti, I., Gozzetti, A., Calabrese, S., Crupi, R., Chitarrelli, I., & Lauria, F. (2012). PERSISTENCE OF PH+/CD34+ CELLS IN CHRONIC MYELOID LEUKEMIA PATIENTS IN PROLONGED COMPLETE CYTOGENETIC REMISSION FOLLOWING IMATINIB MESYLATE TREATMENT. Journal of the Siena Academy of Sciences, 1(1), 15–17. https://doi.org/10.4081/jsas.2009.329

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC